The inability of Ranbaxy Laboratories to get its generic of heart drug Diovan to market for 18 months has been a boon for Novartis ($NVS). Not so much for consumers. The way Bloomberg figures it, consumers and the U.S. government have lost out on ... FiercePharma, 2 days ago
Heart Drug Costs $900 Million More as Generic Held Back: Health - Washington Post, 3 days ago
Ranbaxy's Woes Add $900 Million to U.S. Heart Drug Costs - Bloomberg, 3 days ago
Will the deal further delay or hasten launch of generic Diovan, Nexium? Share Tools Daiichi Sankyo should be out from under Ranbaxy Laboratories by the end of the year. The Japanese drugmaker today released its road map for the $3.2 billion ...FiercePharma, 6 days ago
Medical Editor: What are the different types of high blood pressure (hypertension) medicines? There are many types of drugs used to treat high blood pressure (hypertension), including calcium channel blockers (CBCs) such as Norvasc ...RxList, 2 weeks ago What You Need to Know About High Blood Pressure Drugs Motley Fool, 2 weeks ago
Cardiovascular Diseases Therapeutics in Major Developed Markets to 2019 - Increasing Prevalence and Promising Novel Drugs offset Patent Cliff Threat
LONDON Summary GBI Research has released its pharmaceutical research, "", which provides insights into three cardiovascular therapeutic indications in the top eight markets of the US, the UK, Germany Scope - Disease overview and treatment usage ...PR Newswire, 1 month ago
on your WebpageAdd Widget >Get your members hooked!